Results 101 to 110 of about 961 (200)

CLINICAL EFFECTIVENESS AND ANTIOXIDANT ACTIVITY OF MILDRONATE IN ISCHEMIC STROKE

Российский кардиологический журнал, 2009
.
M. Yu. Maksimova, B. A. Kistenev, M. A. Domashenko, T. N. Fedorova, T. N. Sharypova   +4 more
openaire   +1 more source

CYTOPROTECTOR MILDRONATE IN CORRECTING MYOCARDIAL DYSFUNCTION AMONG STABLE ANGINA PATIENTS AFTER CORONARY REVASCULARISATION

Российский кардиологический журнал, 2009
In total, 149 patients, aged 41–75 years, with Functional Class (FC) II-III stable angina, who underwent coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI), were examined.
I. G. Gordeev, E. E. Luchinkina, S. V. Hegay   +2 more
doaj  

Unlocking the Potential of Meldonium: From Performance Enhancement to Therapeutic Insights

Psychoactives
Meldonium, a promising pharmacological agent initially developed for cardiovascular indications, has sparked considerable interest in recent years due to its potential performance-enhancing effects.
Val Bellman
doaj   +1 more source

Mildronate efficacy and tolerance in chronic heart failure patients therapy

Российский кардиологический журнал, 2005
.
A. S. Galiavich, Z. M. Galeeva, Z. V. Baleeva   +2 more
openaire   +1 more source

A tennis lesson : sharp practice in the science behind the Sharapova case [PDF]

, 2016
Abrahamsson, Abrahamsson, Arduino Arduini, Giudice, Jaudzems, Liepinsh, Longo, Rasmussen, Seiler, Simkhovich, Victor A Zammit, Zammit   +11 more
core   +1 more source

EFFECTS OF MILDRONATE, AS A PART OF COMBINED HEART FAILURE THERAPY, ON CARBOHYDRATE AND LIPID METABOLISM AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Российский кардиологический журнал, 2010
In total, 100 patients aged 45-70 years, with Functional Class (FC) II-III chronic heart failure (CHF) and compensated or sub-compensated Type 2 diabetes mellitus (DM-2) were examined.
M. E. Statsenko, S. V. Turkina, S. V. Belenkova, L. V. Poletaeva, G. P. Dudchenko   +4 more
doaj  

Lipid peroxidation and protective antioxidant systems in coronary bypass surgery and cardioprotective therapy

Российский кардиологический журнал, 2005
Оn-pump coronary bypass surgery was performed in 58 stable angina patients aged 43-72. Group I (n = 19) received standard coronary heart disease (CHD) treatment, together with mildronate: before the surgery, 750 mg/d for 3 days, then 750 mg/d twice a ...
I. G. Gordeev, E. E. Ilina, V. A. Lusov, N. A. Volov, E. A. Bekchiu, A. Yu. Lebedeva   +5 more
doaj  

CRIP1 suppresses BBOX1-mediated carnitine metabolism to promote stemness in hepatocellular carcinoma. [PDF]

EMBO J, 2022
Wang J, Zhou Y, Zhang D, Zhao W, Lu Y, Liu C, Lin W, Zhang Y, Chen K, Wang H, Zhao L.   +10 more
europepmc   +1 more source

Endothelial dysfunction in heart failure with normal systolic function, and its correction with a metabolic agent, mildronate

Российский кардиологический журнал, 2005
To assess the influence of a metabolic agent, mildronate, on endothelial function in chronic heart failure (CHF) with normal systolic function, 105 patients with I-IIA Stage, II-III Functional Class (FC) CHF, and normal left ventricular systolic function,
V. P. Geychenko, A. V. Kuryata, O. V. Muzhchil   +2 more
doaj  

Structure of mildronate, its pharmaceutical salts and cocrystals [PDF]

Acta Crystallographica Section A Foundations of Crystallography, 2011
A. Mishnev, I. Kalvins, L. Aleksejeva, A. Lebedev   +3 more
openaire   +1 more source